Walleye Capital
CMLFU

Walleye Capital’s CM Life Sciences, Inc. Unit CMLFU Stock Holding History

Walleye Capital’s Portfolio CMLFU Stock Details CMLFU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-11,080
Closed -$129 – 1539
2020
Q4 		$129 Sell
11,080
-15,920
-59% -$172K 0.01% 787
2020
Q3 		$283K Buy
+27,000
New +$284K 0.03% 519

Other funds holding CMLFU

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCP
Berylson Capital Partners Boston, Massachusetts $41.2M AUM 0.19% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
IM
Islet Management New York $49.1M AUM 17.59% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
GA
Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
ACM
Arrow Capital Management New York $144M AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Walleye Capital's CMLFU Position: Q1 2021 in Review

Walleye Capital sold out of CM Life Sciences, Inc. Unit (CMLFU) in Q1 2021, closing a stake of 11,080 shares — an estimated $129 sold.

Walleye Capital first reported a position in CMLFU in Q3 2020 and held it in 2 quarters. The position peaked at $283K in Q3 2020. 21 funds tracked by Wall St. Rank hold CMLFU as of Q1 2021.

  • Walleye Capital reported no remaining CM Life Sciences, Inc. Unit position as of Q1 2021 after selling out during the quarter.
  • Walleye Capital sold 11,080 CM Life Sciences, Inc. Unit shares in Q1 2021, an estimated $129.
  • Walleye Capital first reported a position in CM Life Sciences, Inc. Unit in Q3 2020 and held it in 2 quarters.
  • Walleye Capital's CM Life Sciences, Inc. Unit position peaked at $283K in Q3 2020.
  • 21 funds tracked by Wall St. Rank held CM Life Sciences, Inc. Unit as of Q1 2021.

Based on Walleye Capital's 13F filing for Q1 2021, filed 17 May 2021.